NIH Resubmission (A1): 1 Try, 37 Months, 1-Page Intro

Full answer: NIH allows one A1 resubmission after an unfunded A0 application when the funding opportunity accepts resubmissions. According to NIH, the A1 must include a one-page Introduction that responds to the summary statement, and NIH policy gives applicants 37 months after the original A0 submission. The real decision isn't "resubmit or give up." Ask whether the summary statement points to fixable review concerns, a different NIH activity code, or a fresh A0 route.

How to Resubmit an NIH Grant: A1 Strategy, the Introduction Page, and When to Start Fresh

Data note: Source rules were checked again on June 2, 2026 against NIH resubmission policy, NIH application-policy pages, NIH application guides, and Grantsights NIH program records. Program parameters can change when NIH updates a NOFO or application guide.

Who this is for: NIH applicants who received their summary statement and weren't funded, whether they were scored but outside the payline or triaged without discussion. Also useful for mentors and research administrators advising investigators on resubmission strategy.

Here's the reality of NIH funding: many investigators do not get funded on their first submission. The system is designed to be iterative. Your A0 submission is often a first draft that gets refined through review. The NIH resubmission is not a sign of failure. It is a normal part of the funding cycle. For context on all the NIH mechanisms worth pursuing alongside your R01, see the complete NIH grants guide, the NIH R01 grant path, and the R01 success-rate data guide.

But not all resubmissions are created equal. The investigators who turn unfunded A0s into funded A1s are the ones who treat the resubmission strategically, not just as a chance to fix typos and add data.

Last updated: June 2, 2026

What NIH Official Pages Do Not Decide For You

According to NIH, a resubmission is a modified unfunded application, only one A1 is accepted, and the resubmission must be allowed by the funding opportunity. According to NIH policy, an overlapping A1 cannot be submitted before the summary statement is issued. According to NIH guidance effective May 25, 2024, changes in a resubmission should be described in the Introduction, not marked throughout the application as a visual-change exercise.

What the official pages do not tell you is whether your A1 is worth spending the next cycle on. Grantsights analysis of NIH route evidence uses a three-part screen:

For example, one PI with a strong R01 premise but a weak recruitment plan should usually spend the A1 on feasibility evidence and letters. A PI whose triaged A0 was criticized for the central hypothesis should usually write a new A0 instead of burning the only A1 on cosmetic fixes. The NIH grant search is useful when the decision turns on whether a nearby mechanism is a better fit, and NIH RePORTER shows award sizes and past recipients.

---

The A1 Resubmission: Rules and Timeline

What "A1" Means

NIH labels applications with version numbers:

• A0: Your initial (new) submission
• A1: Your first and only resubmission

NIH eliminated the A2 (second resubmission) in 2009. You get one resubmission per application. If your A1 isn't funded, you can continue the work as a new A0 that follows new-application rules.

Timeline

Practical timing: If you submit an R01 A0 on February 5, your summary statement may arrive around July. You could often target the next cycle if the source NOFO accepts resubmissions and the summary statement is out. According to NIH's standard due-date table, new R01s and resubmission R01s use different standard date lanes, so confirm the exact application type before setting the calendar.

Resubmission Receipt Dates

A1 resubmissions follow different receipt dates than new applications:

---

Step 1: Read Your Summary Statement Carefully

Your summary statement is the roadmap for your resubmission. It contains the detailed critiques from your three assigned reviewers plus any additional comments from the discussion (if your application was discussed).

What to Look For

Strengths that all reviewers agreed on. These are the parts of your application that work. Don't change them substantially in the resubmission.

Weaknesses that all reviewers mentioned. If all three reviewers flagged the same problem, you must address it. This is non-negotiable.

Weaknesses that only one reviewer raised. These still need to be addressed, but you have more flexibility in how you respond.

The overall tone. Did reviewers seem excited about the science but concerned about methods? Or did they question the premise itself? The tone tells you whether a resubmission is viable.

Score Interpretation

---

Step 2: Decide Whether to Resubmit or Submit as New

This is the most underappreciated decision in NIH grant strategy. Not every unfunded application should be resubmitted.

Resubmit as A1 When:

• Reviewers liked the concept but had methodological concerns. "The question is important but the approach needs strengthening" is the ideal setup for a resubmission.
• The critiques are specific and addressable. "Aim 2 lacks a control group" or "Power analysis is missing" are problems you can fix.
• Your score was close to the payline. Scores in the 20s-30s often become funded scores with targeted improvements.
• You want the same study section. A1 resubmissions typically go to the same study section, which means reviewers who already know your work evaluate the improvements.

Submit as New A0 When:

• Reviewers questioned the scientific premise. If the fundamental idea is being challenged, no amount of revision will satisfy those reviewers. You need fresh eyes.
• You want to substantially change the scope. If you're adding or removing specific aims, changing the population, or shifting the methodology dramatically, a new A0 gives you a clean slate.
• You want a different study section. If you believe your application was reviewed by the wrong panel, a new A0 lets you request a different assignment.
• Your A0 was triaged with very low preliminary scores. Reviewers who saw a triaged A0 may have anchoring bias. Fresh reviewers won't carry that baggage.
• The field has changed. If new publications have altered the context of your research, a new A0 lets you frame the work in the current context without being compared to an outdated version.

Advice: If your A0 scored in the 40s or was triaged, think hard before spending your one resubmission. You might be better off reworking the application substantially and submitting as a new A0, saving the A1 option for when you have a stronger submission that's more likely to benefit from targeted revisions.

Bad Fit For An A1

Skip the A1 path when the resubmission would mostly defend the old application. Bad-fit signals include a premise critique, a review-group mismatch, no new feasibility evidence, a changed study population, a changed activity code, or a plan to move from a program announcement to an RFA. NIH says some route changes require a new application, and reviewers can recognize when an A1 is just the old A0 with a one-page apology.

---

Step 3: Write the Introduction Page

The Introduction is a one-page document that appears at the beginning of your A1 resubmission. It's your opportunity to show reviewers that you've listened to their feedback and improved the application.

Format That Works

The most effective format is straightforward:

Opening paragraph (2-3 sentences): Thank the reviewers, briefly summarize the main themes of their feedback, and state that you've made substantial revisions.

Concern-by-concern responses: List each major criticism and your response. Use formatting to make it easy to scan:

Reviewer concern: [Paraphrase the concern in bold] Response: [Explain what you changed and why, in regular text]

What to Include

• Every major weakness mentioned by any reviewer
• Specific changes you made, with page or section references (e.g., "We have added a power analysis on page 8 of the Research Strategy")
• New preliminary data that addresses feasibility concerns
• Changes to scope or aims if warranted by the critiques

What to Avoid

• Quoting reviewers verbatim. Paraphrase their concerns. Direct quotes can come across as confrontational.
• Being defensive. Never write "the reviewer misunderstood" or "this criticism is incorrect." Even when a reviewer is wrong, frame your response positively: "We have clarified this point by..."
• Arguing with reviewers. If you disagree with a concern, acknowledge it, explain your reasoning for not changing it, and provide evidence supporting your approach.
• Ignoring any criticism. Reviewers notice when their concerns aren't addressed. Even minor points deserve a brief response.
• Going over one page. This is a hard limit. Be concise.

Example Response Patterns

When you agree with the criticism: "Reviewers noted that the sample size for Aim 2 was not adequately justified. We have added a formal power analysis (page 9) based on preliminary data from our pilot study, which supports a sample of 120 participants to detect a 15% difference with 80% power."

When you partially agree: "Reviewers expressed concern about the feasibility of recruiting 200 participants in Year 1. We've revised the recruitment plan to include two additional clinical sites (see Letters of Support) and adjusted the timeline to allow 18 months for enrollment rather than 12."

When you respectfully disagree: "One reviewer suggested using Method X instead of Method Y for Aim 3. We have carefully considered this suggestion and provide additional justification for our use of Method Y on page 11, including recent publications (Smith et al., 2025; Jones et al., 2026) demonstrating its superior sensitivity in our specific experimental context. However, we have added Method X as a complementary analysis to strengthen our conclusions."

---

Step 4: Revise the Application Strategically

What to Change

Everything the reviewers asked for (unless you have a strong, evidence-based reason not to). This includes:

• Adding missing controls or analyses
• Strengthening the power analysis or sample size justification
• Adding new preliminary data
• Revising the approach to address feasibility concerns
• Adjusting the budget or timeline
• Adding collaborators or letters of support

Text that marks changes. NIH requires that you indicate changes in the A1 by using brackets, italics, bold, or other formatting to help reviewers identify revisions. Many applicants use vertical lines in the margin or bold text for new content.

What Not to Change

The parts reviewers praised. If all three reviewers said your Significance section was strong, don't rewrite it. Changing things that worked can backfire.

The overall structure and framing (unless reviewers explicitly critiqued it). Reviewers expect to see a recognizable evolution of the same application, not an entirely different proposal.

Adding New Preliminary Data

If the reviewers' main concern was feasibility ("How do we know this will work?"), new preliminary data is your strongest tool. Even a small dataset or pilot experiment that demonstrates your approach works can transform reviewer confidence.

Plan your data collection immediately after reading the summary statement. If you need 4 months of experiments to generate the data and 2 months to write the revision, that means submitting your A1 roughly 6 months after receiving the summary statement.

Use Grantsights route evidence before you commit the cycle. If the same scientific plan could fit a smaller pilot mechanism, compare the NIH R03 route. If it needs exploratory proof, compare the Parent R21 route. If it is a career-stage issue, compare the NIH K award index. This keeps the A1 from becoming the default answer when the review problem is actually scope or mechanism fit.

---

The "One Resubmission" Rule: What Happens After an Unfunded A1

If your A1 isn't funded, you've used your one resubmission. Your options:

Submit a New A0

You can submit a new A0 application after an unfunded A1. A common mistake is believing it must be scientifically different: NOT-OD-18-197 says there is no administrative requirement that the science in a new A0 be substantively different from any previously reviewed submission.

What the notice does forbid, anywhere in a new A0 including letters and attachments:

• An Introduction responding to critiques from a previous review
• Any mention of previous overall or criterion scores or percentiles
• Any mention of comments made by previous reviewers
• Any description of how the application changed since its last submission

Whether to change the aims is a strategy call, not a rule. If reviewers doubted the central premise, a reworked approach is usually worth it; if they liked the science but the application was outside the payline, the same aims in a cleaner new A0 can be reasonable.

Change the Mechanism

If your R01 wasn't funded after an A0 and A1, you could submit a related project as an R21 (if it's genuinely exploratory) or as an R03 (if a smaller scope makes sense). This isn't a resubmission; it's a different mechanism and a different application.

Change the Institute

You can request that your new A0 be assigned to a different institute. If you believe the first institute's payline was the problem, targeting an institute with a more generous payline might help. Check institute-specific success rates before deciding.

---

Resubmission Success Rates: What the Numbers Can Tell You

NIH's Data Book success-rate tables report rates by mechanism and institute but don't separate first submissions from resubmissions, so be careful with any single A1 success rate quoted without a source. Grantsights doesn't publish one.

Why resubmissions often do better when they do:

1. Self-selection: Investigators who received good-but-not-funded scores are more likely to resubmit, while those with poor scores often don't.
2. Improved applications: Addressing reviewer concerns genuinely makes the application stronger.
3. Reviewer familiarity: Study section members who reviewed the A0 can see the improvements, which builds confidence.
4. Persistence signal: A well-revised A1 demonstrates that the investigator is responsive and committed.

For new investigators, the A1 success rate combined with the ESI payline advantage makes resubmission an especially strong strategy.

---

When Your Application Was Triaged (Not Discussed)

Normally about half of NIH applications aren't discussed at the study section meeting. Under NIH's temporary review process (NOT-OD-26-114), which stays in place through the January 2027 Advisory Council, most meetings discuss only 30% to 35% of applications. The middle third are designated "competitive but not discussed" and the lowest third "not competitive and not discussed". You still receive written critiques from your three reviewers, but no overall impact score.

How to Handle a Triaged Application

Don't panic. Being triaged is common, especially for new investigators. It doesn't mean your science is bad. It means reviewers had concerns that kept your application from the top half.

Read the critiques carefully. Even without discussion, the written reviews tell you what the problems were. Look for patterns across all three reviewers.

Decide between A1 and new A0. If the critiques point to fixable issues (methodology, preliminary data, scope), an A1 resubmission makes sense. If the critiques question the premise or significance, a new A0 with a different framing may be better.

Talk to your program officer. After receiving a triaged summary statement, contact the program officer at your assigned institute. They can provide context that isn't in the written critiques and advise on whether resubmission is worthwhile.

---

Why Most A1 Resubmissions Still Don't Get Funded, and What the Ones That Do Have in Common

Even a resubmission that answers every critique can go unfunded, especially in a year with tight paylines. So what separates the ones that make it from the ones that don't?

The funded A1s don't just respond to reviewer critiques: they reorganize the Research Strategy around the critique. For example, if reviewers doubted the feasibility of Aim 2, restructure Aim 2 itself, move the supporting data from the background into the experimental design, and cut any sub-aim reviewers called tangential. Adding a paragraph to the same structure rarely changes a reviewer's mind.

The one-page introduction is the most misused section in the resubmission. Some introductions list every reviewer comment and say "addressed in revised Research Strategy." That approach tells reviewers you read the critiques; it doesn't tell them anything was fixed. An effective introduction spends half its space on the one or two critiques that could have killed the application and shows, in two to three sentences each, how the revision responds. Don't itemize everything. Prioritize the problems that mattered.

As of February 2024, NIH eliminated the requirement to mark changes with bracketing or special typography in resubmission text. This changed how reviewers read A1s in ways that applicants don't anticipate. When changes were flagged with brackets, reviewers could quickly scan what was new. Now they have to read the whole Research Strategy. This means your resubmission must read as a coherent, complete document, not a patched version of the original. Treating the removal of bracketing as an invitation to make minimal edits is a mistake. The standard is now higher, not lower.

The honest truth is that some applications can't be saved with a resubmission. If reviewers questioned the fundamental premise or significance of the science, an A1 that adds better methods to a concept reviewers found unimportant won't work. Investigators can invest months in A1 revisions when the smarter move would be a genuine reframe as a new A0 with a different specific aim structure. Talk to your program officer before you decide: not after you've already written the A1, but before.

What NIH Doesn't Tell You About Resubmissions

The official resubmission guidance covers the mechanics. Here's the strategic knowledge that comes from watching the process from the inside.

The "new A0 after failed A1" strategy has risks. When you submit a new A0 that's similar to a failed A0/A1, there's a chance it gets assigned to the same study section and even the same reviewers. If those reviewers recognize the application, they may be more critical, not less. To avoid this, make genuine, substantive changes and consider requesting a different study section in your cover letter.

Some reviewers read the Introduction first. Even though the Introduction is at the beginning of the application, not all reviewers start there. Some read the entire Research Strategy first and then check the Introduction to see if their concerns match the previous review. This means your Research Strategy must stand on its own, not rely on the Introduction for context.

The best resubmissions look like they would have been funded even without the A0. If your A1 is strong enough to be funded on its own merits, independent of the resubmission context, you're in great shape. If it only makes sense in light of the A0 critiques, it's weaker. Aim for an application that a brand-new reviewer (who never saw the A0) would score highly.

Timing your A1 matters. Study sections meet three times a year, and the composition of the panel shifts slightly each meeting. Submitting your A1 for the same study section meeting a year later means some of your original reviewers may have rotated off. This can be good (fresh eyes) or bad (loss of continuity). There's no universal answer, but it's worth discussing with your program officer.

---

A Resubmission Checklist

Before submitting your A1, verify:

• [ ] Introduction page is exactly one page, addresses every major critique
• [ ] Changes are marked throughout the application (brackets, bold, margin marks)
• [ ] New preliminary data is included where reviewers requested it
• [ ] Budget and timeline adjustments reflect any scope changes
• [ ] Letters of support are updated (especially if you've added collaborators)
• [ ] Specific Aims page is revised to address reviewer concerns about framing
• [ ] You've had at least 2 external colleagues read the revised application
• [ ] You've contacted the program officer to discuss your resubmission plan
• [ ] Your grants office knows the A1 receipt date (different from A0 dates)
• [ ] You haven't inadvertently changed parts that reviewers praised

For help with the Specific Aims revision, see our Specific Aims guide. For understanding reviewer scores and language, see our summary statement guide.

---

Sources

• NIH Resubmission Applications: https://www.grants.nih.gov/grants-process/submit/submission-policies/resubmission-applications
• NIH Grants Policy Statement, Policies Affecting Applications: https://grants.nih.gov/grants/policy/nihgps/HTML5/section_2/2.3.7_policies_affecting_applications.htm
• NOT-OD-24-061, Marking Changes in Resubmission Applications: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-24-061.html
• NOT-OD-18-197, NIH/AHRQ Submission and Resubmission Policy: https://grants.nih.gov/grants/guide/notice-files/not-od-18-197.html
• NIH Standard Due Dates: https://grants.nih.gov/grants/how-to-apply-application-guide/due-dates-and-submission-policies/due-dates.htm
• NIH Success Rates by Submission Type: https://report.nih.gov/funding/nih-budget-and-spending-data-past-fiscal-years/success-rates
• NIH RePORTER: https://reporter.nih.gov/
• NIH Center for Scientific Review: https://public.csr.nih.gov/